Gonadorelin vs Progesterone
A side-by-side research comparison of Gonadorelin and Progesterone across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Gonadorelin | Progesterone |
|---|---|---|
| Full name | Gonadorelin (GnRH Analog) | Micronized Progesterone (Prometrium) |
| Category | Hormone Replacement | Hormone Replacement |
| Status | FDA Approved | FDA Approved |
| Mechanism | Binds GnRH receptors on pituitary gonadotrophs to stimulate LH and FSH release, maintaining testicular/ovarian function and natural sex hormone production. | Agonizes progesterone receptors and GABA-A receptors (via allopregnanolone metabolite). Inhibits 5-alpha reductase, opposes estrogen proliferative effects, and promotes myelination in neural tissue. |
| Molecular weight | 1182.39 Da | 314.46 Da |
| Half-life | ~10-40 minutes | ~16-18 hours (oral micronized) |
| Bioavailability | ~90% subcutaneous | ~10% oral (first-pass); ~100% topical/vaginal |
| Typical dose | 100-500 mcg | 100-200 mg oral or 20-40 mg topical |
| Frequency | 2-3x per week or pulsatile | Nightly (oral) or daily (topical) |
| Route | Subcutaneous injection | Oral capsule, topical cream, or vaginal |
Gonadorelin reported benefits
- Maintains natural hormone production
- Fertility preservation
- Testicular function support
- LH/FSH normalization
Progesterone reported benefits
- Enhanced deep sleep (GABA modulation)
- Neuroprotection
- Estrogen opposition
- Reduced anxiety
- DHT reduction (5AR inhibition)
- Cardiovascular protection
Related comparisons
Research and educational reference only. Not medical advice.